Vivo Ventures is a life-sciences focused venture capital firm formed in 1996 with over $650M under management. Vivo Ventures is currently making investments from its $275M sixth fund into promising biotechnology and life science companies.

With over 90 years of scientific and operational expertise in biotechnology, Vivo makes investment decisions for the Funds and helps its portfolio companies develop corporate strategy, arrange licensing agreements and strategic alliances, recruit key management personnel, and acquire new products and technology to accelerate growth. Its current portfolio includes more than 60 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.




Recent News

APT Pharmaceuticals Secures $32 Million in Series B Financing
Burlingame, CA - September 30, 2008

Sagent Completes $30 Million Series A Financing Extension
Schaumburg, IL - September 4, 2008

SpectraGenics Announces $30M in New Funding Changes Company Name to Tria Beauty
Pleasanton, CA - July 10, 2008

AVANIR to Raise $40.0 Million to Fund Zenvia Through Clinical Development and Regulatory Approval
Aliso Viejo, CA - March 27, 2008

Carbylan Announces $20 Million Series B Financing
Palo Alto, CA - Nov 26, 2007

Yaupon Therapeutics closes $14.5 million financing -- Series C financing positions company to advance development of its product portfolio targeting cancer and central nervous system diseases
Radnor, PA - Nov 26, 2007